The business model employed by Phylogica has not generated successful outcomes in terms of the licensing of phylomer drug candidates. All the while, however, the science has advanced, partly on the back of revenues from Big Pharma and an exchange of ideas through the various collaborations.
The final straw for many shareholders was the collapse of the Janssen collaboration. Unless you follow the science and have confidence in the management team to deliver in the future, there appears little to like about Phylogica.
Given that the science has led Phylogica to the forefront of the intracellular delivery of therapeutic cargoes or in the case of IMB, intracellular protein-protein interactions, a game-changing moment is always a signature away.
PYC Price at posting:
1.4¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)